130 related articles for article (PubMed ID: 9703278)
1. Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.
Larsson R; Dhar S; Ehrsson H; Nygren P; Lewensohn R
Br J Cancer; 1998 Aug; 78(3):328-35. PubMed ID: 9703278
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
Anticancer Drugs; 2003 Sep; 14(8):617-24. PubMed ID: 14501383
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
Gullbo J; Wallinder C; Tullberg M; Lövborg H; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
Mol Cancer Ther; 2003 Dec; 2(12):1331-9. PubMed ID: 14707274
[TBL] [Abstract][Full Text] [Related]
4. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.
Lewensohn R; Ehrsson H; Hansson J; Ringborg U
Anticancer Res; 1991; 11(1):321-4. PubMed ID: 2018366
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.
Lewensohn R; Fernberg JO; Ehrsson H; Merlini G
Med Oncol Tumor Pharmacother; 1991; 8(4):265-9. PubMed ID: 1820493
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells.
Hansson J; Lewensohn R; Ringborg U
Anticancer Res; 1991; 11(5):1725-30. PubMed ID: 1768043
[TBL] [Abstract][Full Text] [Related]
7. Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio.
Lewensohn R; Hansson J; Ringborg U; Ehrsson H
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):783-8. PubMed ID: 3653195
[TBL] [Abstract][Full Text] [Related]
8. Derivatives of melphalan designed to enhance drug accumulation in cancer cells.
Kupczyk-Subotkowska L; Tamura K; Pal D; Sakaeda T; Siahaan TJ; Stella VJ; Borchardt RT
J Drug Target; 1997; 4(6):359-70. PubMed ID: 9239576
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxicity of peptichemio compared to melphalan and meta-DL-sarcolysin.
Morasca L; Erba E
Eur J Cancer (1965); 1980 Aug; 16(8):1105-9. PubMed ID: 7439225
[No Abstract] [Full Text] [Related]
10. Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide.
Roboz J; Jiang J; Holland JF; Bekesi JG
Cancer Res; 1997 Nov; 57(21):4795-802. PubMed ID: 9354441
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.
Ehrsson H; Lewensohn R; Wallin I; Hellström M; Merlini G; Johansson B
Cancer Chemother Pharmacol; 1993; 31(4):265-8. PubMed ID: 8422688
[TBL] [Abstract][Full Text] [Related]
12. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
Kupczyk-Subotkowska L; Siahaan TJ; Basile AS; Friedman HS; Higgins PE; Song D; Gallo JM
J Med Chem; 1997 May; 40(11):1726-30. PubMed ID: 9171882
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity and effect on collagen biosynthesis of proline analogue of melphalan as a prolidase-convertible prodrug in cultured human skin fibroblasts.
Chrzanowski K; Bielawska A; Bielawski K; Wołczyński S; Pałka J
Farmaco; 2001 Sep; 56(9):701-6. PubMed ID: 11680815
[TBL] [Abstract][Full Text] [Related]
14. Chemical modification of melphalan as a key to improving treatment of haematological malignancies.
Gajek A; Poczta A; Łukawska M; Cecuda-Adamczewska V; Tobiasz J; Marczak A
Sci Rep; 2020 Mar; 10(1):4479. PubMed ID: 32161295
[TBL] [Abstract][Full Text] [Related]
15. Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan.
Gupta V; Singh SV; Ahmad H; Medh RD; Awasthi YC
Biochem Pharmacol; 1989 Jun; 38(12):1993-2000. PubMed ID: 2742603
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
17. DNA-damage in human cells treated with the closely related alkylating agents peptichemio, m-L-sarcolysin and melphalan.
Ringborg U; Lambert B; Lewensohn R; Turesson I
Eur J Cancer Clin Oncol; 1981 Sep; 17(9):991-6. PubMed ID: 7198989
[No Abstract] [Full Text] [Related]
18. The effect of the preparation "Peptichemio" on leukopoiesis and experimental tumours of animals compared with that of sarcolysin and thiophosphamide.
Balitsky KP; Veksler IG; Tsapenko VF; Kavetsky RE
G Ital Chemioter; 1980; 27(1):1-5. PubMed ID: 6793439
[No Abstract] [Full Text] [Related]
19. Effects of an antitumor multipeptide complex on immunocompetent and antigen-responsive cells.
De Barbieri A; Golferini A; Brugo A; Omesso A; Tassi GC
Boll Ist Sieroter Milan; 1976 Jul; 55(3):201-15. PubMed ID: 1087883
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Jonsson E; Fridborg H; Csóka K; Dhar S; Sundström C; Nygren P; Larsson R
Br J Cancer; 1997; 76(2):211-9. PubMed ID: 9231921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
